RealSpark personal page - To The Moon

RealSpark

RealSpark

No personal profile

71Follow

20Followers

0Topic

0Badge

2025-02-13

$海庭(5E2.SI)$ What happened today?

2021-01-27

?

Beikang Medical-B starts its IPO today, and the entrance fee is approximately HK$13,817.85

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3573538830673442","uuid":"3573538830673442","gmtCreate":1611207048400,"gmtModify":1611665929786,"name":"RealSpark","pinyin":"realspark","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/b69a293621bf72e2cde1e1d06880efa1","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":20,"headSize":71,"tweetSize":113,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":2,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.03.02","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.57%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"cbe1c45c584340f3bd9ae6c77e0e9981-1","templateUuid":"cbe1c45c584340f3bd9ae6c77e0e9981","name":"Academy Experiencer","description":"5 lessons learned","bigImgUrl":"https://community-static.tradeup.com/news/fb5ae275631fb96a92d475cdc85d2302","smallImgUrl":"https://community-static.tradeup.com/news/c2660a1935bd2105e97c9915619936c3","grayImgUrl":null,"redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":2006},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.30%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":6,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":9,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":403103477887104,"gmtCreate":1739441540423,"gmtModify":1739502901873,"author":{"id":"3573538830673442","authorId":"3573538830673442","name":"RealSpark","avatar":"https://static.tigerbbs.com/b69a293621bf72e2cde1e1d06880efa1","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573538830673442","idStr":"3573538830673442"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/5E2.SI\">$海庭(5E2.SI)$ </a> What happened today?&nbsp;","listText":"<a href=\"https://ttm.financial/S/5E2.SI\">$海庭(5E2.SI)$ </a> What happened today?&nbsp;","text":"$海庭(5E2.SI)$ What happened today?","images":[{"img":"https://community-static.tradeup.com/news/5323bf900bfc1a60abc96ec51977a233","width":"882","height":"1664"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":57,"commentSize":0,"repostSize":1,"link":"https://ttm.financial/post/403103477887104","isVote":1,"tweetType":1,"viewCount":1881,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":313620068,"gmtCreate":1611710481354,"gmtModify":1704862246167,"author":{"id":"3573538830673442","authorId":"3573538830673442","name":"RealSpark","avatar":"https://static.tigerbbs.com/b69a293621bf72e2cde1e1d06880efa1","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573538830673442","idStr":"3573538830673442"},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/313620068","repostId":"1148412616","repostType":4,"repost":{"id":"1148412616","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1611707484,"share":"https://ttm.financial/m/news/1148412616?lang=en_US&edition=fundamental","pubTime":"2021-01-27 08:31","market":"hk","language":"zh","title":"Beikang Medical-B starts its IPO today, and the entrance fee is approximately HK$13,817.85","url":"https://stock-news.laohu8.com/highlight/detail?id=1148412616","media":"老虎资讯综合","summary":"1月27日，贝康医疗-B发布公告，将于1月27日-2月1日招股，公司拟发行6666.7万股股份，其中公开发售666.7万股，国际发售6000万股，每股发行价26.36-27.36港元，每手500股，预","content":"<p>On January 27,<a href=\"https://laohu8.com/S/02170\">Beikang Medical-B</a>It was announced that it will be offered from January 27th to February 1st. The company plans to issue 66.667 million shares, including 6.667 million shares for public offering and 60 million shares for international offering, with an issue price of HK$26.36-27.36 per share and 500 shares per lot. It is expected to be listed on February 8th.</p><p><img src=\"https://static.tigerbbs.com/e70b9d2ed54bdbb42ae460c33ba54400\" tg-width=\"659\" tg-height=\"641\" referrerpolicy=\"no-referrer\"></p><p><b>Subscription ladder:</b></p><p>Group A has 500 shares per lot, and the entrance fee is approximately HK$13,817.85.</p><p>Group B has 200,000 shares, and the funds required for subscription are about 5,527,141.34 Hong Kong dollars.</p><p><img src=\"https://static.tigerbbs.com/4a2a3c6a0dca8a1c930651ef589ee5e4\" tg-width=\"1133\" tg-height=\"762\" referrerpolicy=\"no-referrer\"></p><p>It is reported that Beikang Medical is an innovative platform for genetic testing solutions for assisted reproduction in China. At present, the company has expanded its coverage from the pre-implantation stage to the prenatal and postpartum stages, and is developing a kit at each stage, which makes it a Chinese company whose genetic testing kit product line covers the entire reproductive cycle.</p><p>The company's product, the PGT-A kit, which screens embryos for aneuploidy (a chromosomal disease often associated with implant failure in vitro tube fertilization (IVF)) before implantation, is the first and only NMPA-approved third-generation IVF genetic testing kit, which was registered by the NMPA as a Class III \"innovative medical device\" in February 2020, marking the birth of China's regulated third-generation IVF market, and the company is the only approved kit manufacturer to date.</p><p>In terms of financial data, during the Track Record Period, the Company's revenue was mainly derived from the limited sales of self-developed genetic testing kits for scientific research, as well as the distribution and sale of testing kits, equipment and instruments manufactured by other manufacturers, which were not yet profitable and incurred a net loss. From FY2018 to FY2019, the total revenue of the Company was RMB32.609 million and RMB55.685 million, respectively, representing a year-on-year increase of 70.77%; Net losses of RMB157 million and RMB534 million were recorded during the same periods. In the first nine months of 2020, the company recorded a total revenue of 57.243 million yuan, representing a year-on-year increase of 36.74%, and a net loss of 852 million yuan.</p><p><img src=\"https://static.tigerbbs.com/35761150265524efeb53049d99399a21\" tg-width=\"570\" tg-height=\"793\" referrerpolicy=\"no-referrer\"></p><p>In terms of industry, the reproductive genetics medical device market in China is a relatively emerging market and is developing rapidly. Driven by increasing infertility rates, growing demand for assisted reproductive treatments such as IVF, increasing health awareness in China, increasing availability and availability of genetic testing and technological advancements, the reproductive genetics medical device market in China, in terms of sales revenue based on ex-factory prices, has grown from RMB1.3 billion in 2015 to RMB3.4 billion in 2019 at a CAGR of 28.4% and is expected to reach RMB11.2 billion in 2024 at a CAGR of 26.5% from 2019 to 2024.</p><p>For cornerstone investors, a number of cornerstone investors, including OrbiMed Funds, Lake Bleu Prime, CRF, AHAM, WinTwin, Foresight Funds and IvyRock Fund, agreed to subscribe for the number of Offer Shares available at the Offer Price for an aggregate amount of approximately HK$698 million.</p><p><img src=\"https://static.tigerbbs.com/4781c23410dda3308f5173dc9a41ab5c\" tg-width=\"766\" tg-height=\"523\" referrerpolicy=\"no-referrer\"></p><p>In terms of financing, the Company intends to use the net proceeds from the Share Offer for the following purposes: approximately 30% will be allocated to the core product PGT-A kit; Approximately 20% will be used for clinical trials, registration and commercialization of PGT-M kits; approximately 30% will be allocated for the development, clinical trials and registration filings of our other products; Approximately 10% will be used to enhance research and development capabilities and enhance technology; Approximately 10% will be used for working capital and general corporate purposes.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beikang Medical-B starts its IPO today, and the entrance fee is approximately HK$13,817.85</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeikang Medical-B starts its IPO today, and the entrance fee is approximately HK$13,817.85\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-01-27 08:31</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>On January 27,<a href=\"https://laohu8.com/S/02170\">Beikang Medical-B</a>It was announced that it will be offered from January 27th to February 1st. The company plans to issue 66.667 million shares, including 6.667 million shares for public offering and 60 million shares for international offering, with an issue price of HK$26.36-27.36 per share and 500 shares per lot. It is expected to be listed on February 8th.</p><p><img src=\"https://static.tigerbbs.com/e70b9d2ed54bdbb42ae460c33ba54400\" tg-width=\"659\" tg-height=\"641\" referrerpolicy=\"no-referrer\"></p><p><b>Subscription ladder:</b></p><p>Group A has 500 shares per lot, and the entrance fee is approximately HK$13,817.85.</p><p>Group B has 200,000 shares, and the funds required for subscription are about 5,527,141.34 Hong Kong dollars.</p><p><img src=\"https://static.tigerbbs.com/4a2a3c6a0dca8a1c930651ef589ee5e4\" tg-width=\"1133\" tg-height=\"762\" referrerpolicy=\"no-referrer\"></p><p>It is reported that Beikang Medical is an innovative platform for genetic testing solutions for assisted reproduction in China. At present, the company has expanded its coverage from the pre-implantation stage to the prenatal and postpartum stages, and is developing a kit at each stage, which makes it a Chinese company whose genetic testing kit product line covers the entire reproductive cycle.</p><p>The company's product, the PGT-A kit, which screens embryos for aneuploidy (a chromosomal disease often associated with implant failure in vitro tube fertilization (IVF)) before implantation, is the first and only NMPA-approved third-generation IVF genetic testing kit, which was registered by the NMPA as a Class III \"innovative medical device\" in February 2020, marking the birth of China's regulated third-generation IVF market, and the company is the only approved kit manufacturer to date.</p><p>In terms of financial data, during the Track Record Period, the Company's revenue was mainly derived from the limited sales of self-developed genetic testing kits for scientific research, as well as the distribution and sale of testing kits, equipment and instruments manufactured by other manufacturers, which were not yet profitable and incurred a net loss. From FY2018 to FY2019, the total revenue of the Company was RMB32.609 million and RMB55.685 million, respectively, representing a year-on-year increase of 70.77%; Net losses of RMB157 million and RMB534 million were recorded during the same periods. In the first nine months of 2020, the company recorded a total revenue of 57.243 million yuan, representing a year-on-year increase of 36.74%, and a net loss of 852 million yuan.</p><p><img src=\"https://static.tigerbbs.com/35761150265524efeb53049d99399a21\" tg-width=\"570\" tg-height=\"793\" referrerpolicy=\"no-referrer\"></p><p>In terms of industry, the reproductive genetics medical device market in China is a relatively emerging market and is developing rapidly. Driven by increasing infertility rates, growing demand for assisted reproductive treatments such as IVF, increasing health awareness in China, increasing availability and availability of genetic testing and technological advancements, the reproductive genetics medical device market in China, in terms of sales revenue based on ex-factory prices, has grown from RMB1.3 billion in 2015 to RMB3.4 billion in 2019 at a CAGR of 28.4% and is expected to reach RMB11.2 billion in 2024 at a CAGR of 26.5% from 2019 to 2024.</p><p>For cornerstone investors, a number of cornerstone investors, including OrbiMed Funds, Lake Bleu Prime, CRF, AHAM, WinTwin, Foresight Funds and IvyRock Fund, agreed to subscribe for the number of Offer Shares available at the Offer Price for an aggregate amount of approximately HK$698 million.</p><p><img src=\"https://static.tigerbbs.com/4781c23410dda3308f5173dc9a41ab5c\" tg-width=\"766\" tg-height=\"523\" referrerpolicy=\"no-referrer\"></p><p>In terms of financing, the Company intends to use the net proceeds from the Share Offer for the following purposes: approximately 30% will be allocated to the core product PGT-A kit; Approximately 20% will be used for clinical trials, registration and commercialization of PGT-M kits; approximately 30% will be allocated for the development, clinical trials and registration filings of our other products; Approximately 10% will be used to enhance research and development capabilities and enhance technology; Approximately 10% will be used for working capital and general corporate purposes.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/e2bc484766922e67d87fdb952e5532ab","relate_stocks":{"02170":"贝康医疗-B"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148412616","content_text":"1月27日，贝康医疗-B发布公告，将于1月27日-2月1日招股，公司拟发行6666.7万股股份，其中公开发售666.7万股，国际发售6000万股，每股发行价26.36-27.36港元，每手500股，预期将于2月8日上市。申购阶梯：甲组每手500股，入场费约13817.85港元。乙组头为20万股，申购所需资金约5527141.34港元。据悉，贝康医疗是中国辅助生殖基因检测解决方案的创新平台， 目前公司已经将涉猎范围从植入前阶段扩展至产前和产后阶段，并且正在每个阶段开发一个试剂盒，这使其成为基因检测试剂盒产品线覆蓋整个生殖周期的中国公司。公司的产品PGT-A试剂盒可以在植入前筛查胚胎中的非整倍体（一种经常与试管婴儿(IVF)植入失败相关的染色体疾病），是首个也是唯一已获国家药监局批准的三代试管婴儿基因检测试剂盒，该试剂盒于2020年2月作为三类「创新医疗器械」获国家药监局注册，标志着中国受监管的三代试管婴儿市场的诞生，而公司是迄今唯一获批的试剂盒生产商。财务数据方面，于往绩记录期间，公司收入主要来自于自主开发用于科学研究的基因检测试剂盒的有限销售，以及分销及销售其他厂商生产的检测试剂盒、设备和仪器，尚未盈利，并产生亏损净额。2018财年至2019财年公司总营收分别为人民币3260.9万元及5568.5万元，同比增长70.77%；同期录得净亏损1.57亿元及5.34亿元。2020年前9个月，公司录得总营收5724.3万元，同比增长36.74%，录得净亏损8.52亿元。行业方面，中国生殖遗传学医疗器械市场相对而言属新兴市场且正在快速发展。受不孕率日益上升、对辅助生殖治疗（如试管婴儿）的需求不断增长、中国健康意识日益提升、基因检测的可购性和可用性不断增加以及技术进步所驱动，中国生殖遗传学医疗器械市场（按基于出厂价计算的销售收入计）已从2015年的人民币13亿元增长至2019年的人民币34亿元，复合年增长率为28.4%，并预期于2024年达到人民币112亿元，2019年至2024年的复合年增长率为26.5%。基石投资者方面，多名基石投资者同意按发售价认购可供认购的发售股份数目，总额约6.98亿港元，包括OrbiMed Funds、清池资本(Lake Bleu Prime )、CRF、AHAM、 WinTwin、Foresight Funds 及IvyRock Fund。筹资用途方面，公司拟将股份发售所得款项净额用于以下用途：约30%将分配予核心产品PGT-A试剂盒；约20%将用于PGT-M试剂盒的临床试验、注册申报及商业化；约30%将分配用于我们其他产品的开发、临床试验及注册申报；约10%将用于提高研发能力及提升技术；约10%将用作营运资本及一般企业用途。","news_type":1,"symbols_score_info":{"02170":0.9}},"isVote":1,"tweetType":1,"viewCount":2644,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3527667803686145","authorId":"3527667803686145","name":"社区成长助手","avatar":"https://static.tigerbbs.com/2b7c7106b5c0c8b0037faa67439d898f","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3527667803686145","idStr":"3527667803686145"},"content":"Finally, when you first post [compare heart] [compare heart] post, you can get more exposure by related stocks or related topics. If you want to create high-quality articles, please checkGuidelines for Tiger Community Creation","text":"Finally, when you first post [compare heart] [compare heart] post, you can get more exposure by related stocks or related topics. If you want to create high-quality articles, please checkGuidelines for Tiger Community Creation","html":"Finally, when you first post [compare heart] [compare heart] post, you can get more exposure by related stocks or related topics. If you want to create high-quality articles, please checkGuidelines for Tiger Community Creation"}],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":403103477887104,"gmtCreate":1739441540423,"gmtModify":1739502901873,"author":{"id":"3573538830673442","authorId":"3573538830673442","name":"RealSpark","avatar":"https://static.tigerbbs.com/b69a293621bf72e2cde1e1d06880efa1","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573538830673442","authorIdStr":"3573538830673442"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/5E2.SI\">$海庭(5E2.SI)$ </a> What happened today?&nbsp;","listText":"<a href=\"https://ttm.financial/S/5E2.SI\">$海庭(5E2.SI)$ </a> What happened today?&nbsp;","text":"$海庭(5E2.SI)$ What happened today?","images":[{"img":"https://community-static.tradeup.com/news/5323bf900bfc1a60abc96ec51977a233","width":"882","height":"1664"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":57,"commentSize":0,"repostSize":1,"link":"https://ttm.financial/post/403103477887104","isVote":1,"tweetType":1,"viewCount":1881,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":313620068,"gmtCreate":1611710481354,"gmtModify":1704862246167,"author":{"id":"3573538830673442","authorId":"3573538830673442","name":"RealSpark","avatar":"https://static.tigerbbs.com/b69a293621bf72e2cde1e1d06880efa1","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573538830673442","authorIdStr":"3573538830673442"},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/313620068","repostId":"1148412616","repostType":4,"repost":{"id":"1148412616","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1611707484,"share":"https://ttm.financial/m/news/1148412616?lang=en_US&edition=fundamental","pubTime":"2021-01-27 08:31","market":"hk","language":"zh","title":"Beikang Medical-B starts its IPO today, and the entrance fee is approximately HK$13,817.85","url":"https://stock-news.laohu8.com/highlight/detail?id=1148412616","media":"老虎资讯综合","summary":"1月27日，贝康医疗-B发布公告，将于1月27日-2月1日招股，公司拟发行6666.7万股股份，其中公开发售666.7万股，国际发售6000万股，每股发行价26.36-27.36港元，每手500股，预","content":"<p>On January 27,<a href=\"https://laohu8.com/S/02170\">Beikang Medical-B</a>It was announced that it will be offered from January 27th to February 1st. The company plans to issue 66.667 million shares, including 6.667 million shares for public offering and 60 million shares for international offering, with an issue price of HK$26.36-27.36 per share and 500 shares per lot. It is expected to be listed on February 8th.</p><p><img src=\"https://static.tigerbbs.com/e70b9d2ed54bdbb42ae460c33ba54400\" tg-width=\"659\" tg-height=\"641\" referrerpolicy=\"no-referrer\"></p><p><b>Subscription ladder:</b></p><p>Group A has 500 shares per lot, and the entrance fee is approximately HK$13,817.85.</p><p>Group B has 200,000 shares, and the funds required for subscription are about 5,527,141.34 Hong Kong dollars.</p><p><img src=\"https://static.tigerbbs.com/4a2a3c6a0dca8a1c930651ef589ee5e4\" tg-width=\"1133\" tg-height=\"762\" referrerpolicy=\"no-referrer\"></p><p>It is reported that Beikang Medical is an innovative platform for genetic testing solutions for assisted reproduction in China. At present, the company has expanded its coverage from the pre-implantation stage to the prenatal and postpartum stages, and is developing a kit at each stage, which makes it a Chinese company whose genetic testing kit product line covers the entire reproductive cycle.</p><p>The company's product, the PGT-A kit, which screens embryos for aneuploidy (a chromosomal disease often associated with implant failure in vitro tube fertilization (IVF)) before implantation, is the first and only NMPA-approved third-generation IVF genetic testing kit, which was registered by the NMPA as a Class III \"innovative medical device\" in February 2020, marking the birth of China's regulated third-generation IVF market, and the company is the only approved kit manufacturer to date.</p><p>In terms of financial data, during the Track Record Period, the Company's revenue was mainly derived from the limited sales of self-developed genetic testing kits for scientific research, as well as the distribution and sale of testing kits, equipment and instruments manufactured by other manufacturers, which were not yet profitable and incurred a net loss. From FY2018 to FY2019, the total revenue of the Company was RMB32.609 million and RMB55.685 million, respectively, representing a year-on-year increase of 70.77%; Net losses of RMB157 million and RMB534 million were recorded during the same periods. In the first nine months of 2020, the company recorded a total revenue of 57.243 million yuan, representing a year-on-year increase of 36.74%, and a net loss of 852 million yuan.</p><p><img src=\"https://static.tigerbbs.com/35761150265524efeb53049d99399a21\" tg-width=\"570\" tg-height=\"793\" referrerpolicy=\"no-referrer\"></p><p>In terms of industry, the reproductive genetics medical device market in China is a relatively emerging market and is developing rapidly. Driven by increasing infertility rates, growing demand for assisted reproductive treatments such as IVF, increasing health awareness in China, increasing availability and availability of genetic testing and technological advancements, the reproductive genetics medical device market in China, in terms of sales revenue based on ex-factory prices, has grown from RMB1.3 billion in 2015 to RMB3.4 billion in 2019 at a CAGR of 28.4% and is expected to reach RMB11.2 billion in 2024 at a CAGR of 26.5% from 2019 to 2024.</p><p>For cornerstone investors, a number of cornerstone investors, including OrbiMed Funds, Lake Bleu Prime, CRF, AHAM, WinTwin, Foresight Funds and IvyRock Fund, agreed to subscribe for the number of Offer Shares available at the Offer Price for an aggregate amount of approximately HK$698 million.</p><p><img src=\"https://static.tigerbbs.com/4781c23410dda3308f5173dc9a41ab5c\" tg-width=\"766\" tg-height=\"523\" referrerpolicy=\"no-referrer\"></p><p>In terms of financing, the Company intends to use the net proceeds from the Share Offer for the following purposes: approximately 30% will be allocated to the core product PGT-A kit; Approximately 20% will be used for clinical trials, registration and commercialization of PGT-M kits; approximately 30% will be allocated for the development, clinical trials and registration filings of our other products; Approximately 10% will be used to enhance research and development capabilities and enhance technology; Approximately 10% will be used for working capital and general corporate purposes.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beikang Medical-B starts its IPO today, and the entrance fee is approximately HK$13,817.85</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeikang Medical-B starts its IPO today, and the entrance fee is approximately HK$13,817.85\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-01-27 08:31</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>On January 27,<a href=\"https://laohu8.com/S/02170\">Beikang Medical-B</a>It was announced that it will be offered from January 27th to February 1st. The company plans to issue 66.667 million shares, including 6.667 million shares for public offering and 60 million shares for international offering, with an issue price of HK$26.36-27.36 per share and 500 shares per lot. It is expected to be listed on February 8th.</p><p><img src=\"https://static.tigerbbs.com/e70b9d2ed54bdbb42ae460c33ba54400\" tg-width=\"659\" tg-height=\"641\" referrerpolicy=\"no-referrer\"></p><p><b>Subscription ladder:</b></p><p>Group A has 500 shares per lot, and the entrance fee is approximately HK$13,817.85.</p><p>Group B has 200,000 shares, and the funds required for subscription are about 5,527,141.34 Hong Kong dollars.</p><p><img src=\"https://static.tigerbbs.com/4a2a3c6a0dca8a1c930651ef589ee5e4\" tg-width=\"1133\" tg-height=\"762\" referrerpolicy=\"no-referrer\"></p><p>It is reported that Beikang Medical is an innovative platform for genetic testing solutions for assisted reproduction in China. At present, the company has expanded its coverage from the pre-implantation stage to the prenatal and postpartum stages, and is developing a kit at each stage, which makes it a Chinese company whose genetic testing kit product line covers the entire reproductive cycle.</p><p>The company's product, the PGT-A kit, which screens embryos for aneuploidy (a chromosomal disease often associated with implant failure in vitro tube fertilization (IVF)) before implantation, is the first and only NMPA-approved third-generation IVF genetic testing kit, which was registered by the NMPA as a Class III \"innovative medical device\" in February 2020, marking the birth of China's regulated third-generation IVF market, and the company is the only approved kit manufacturer to date.</p><p>In terms of financial data, during the Track Record Period, the Company's revenue was mainly derived from the limited sales of self-developed genetic testing kits for scientific research, as well as the distribution and sale of testing kits, equipment and instruments manufactured by other manufacturers, which were not yet profitable and incurred a net loss. From FY2018 to FY2019, the total revenue of the Company was RMB32.609 million and RMB55.685 million, respectively, representing a year-on-year increase of 70.77%; Net losses of RMB157 million and RMB534 million were recorded during the same periods. In the first nine months of 2020, the company recorded a total revenue of 57.243 million yuan, representing a year-on-year increase of 36.74%, and a net loss of 852 million yuan.</p><p><img src=\"https://static.tigerbbs.com/35761150265524efeb53049d99399a21\" tg-width=\"570\" tg-height=\"793\" referrerpolicy=\"no-referrer\"></p><p>In terms of industry, the reproductive genetics medical device market in China is a relatively emerging market and is developing rapidly. Driven by increasing infertility rates, growing demand for assisted reproductive treatments such as IVF, increasing health awareness in China, increasing availability and availability of genetic testing and technological advancements, the reproductive genetics medical device market in China, in terms of sales revenue based on ex-factory prices, has grown from RMB1.3 billion in 2015 to RMB3.4 billion in 2019 at a CAGR of 28.4% and is expected to reach RMB11.2 billion in 2024 at a CAGR of 26.5% from 2019 to 2024.</p><p>For cornerstone investors, a number of cornerstone investors, including OrbiMed Funds, Lake Bleu Prime, CRF, AHAM, WinTwin, Foresight Funds and IvyRock Fund, agreed to subscribe for the number of Offer Shares available at the Offer Price for an aggregate amount of approximately HK$698 million.</p><p><img src=\"https://static.tigerbbs.com/4781c23410dda3308f5173dc9a41ab5c\" tg-width=\"766\" tg-height=\"523\" referrerpolicy=\"no-referrer\"></p><p>In terms of financing, the Company intends to use the net proceeds from the Share Offer for the following purposes: approximately 30% will be allocated to the core product PGT-A kit; Approximately 20% will be used for clinical trials, registration and commercialization of PGT-M kits; approximately 30% will be allocated for the development, clinical trials and registration filings of our other products; Approximately 10% will be used to enhance research and development capabilities and enhance technology; Approximately 10% will be used for working capital and general corporate purposes.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/e2bc484766922e67d87fdb952e5532ab","relate_stocks":{"02170":"贝康医疗-B"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148412616","content_text":"1月27日，贝康医疗-B发布公告，将于1月27日-2月1日招股，公司拟发行6666.7万股股份，其中公开发售666.7万股，国际发售6000万股，每股发行价26.36-27.36港元，每手500股，预期将于2月8日上市。申购阶梯：甲组每手500股，入场费约13817.85港元。乙组头为20万股，申购所需资金约5527141.34港元。据悉，贝康医疗是中国辅助生殖基因检测解决方案的创新平台， 目前公司已经将涉猎范围从植入前阶段扩展至产前和产后阶段，并且正在每个阶段开发一个试剂盒，这使其成为基因检测试剂盒产品线覆蓋整个生殖周期的中国公司。公司的产品PGT-A试剂盒可以在植入前筛查胚胎中的非整倍体（一种经常与试管婴儿(IVF)植入失败相关的染色体疾病），是首个也是唯一已获国家药监局批准的三代试管婴儿基因检测试剂盒，该试剂盒于2020年2月作为三类「创新医疗器械」获国家药监局注册，标志着中国受监管的三代试管婴儿市场的诞生，而公司是迄今唯一获批的试剂盒生产商。财务数据方面，于往绩记录期间，公司收入主要来自于自主开发用于科学研究的基因检测试剂盒的有限销售，以及分销及销售其他厂商生产的检测试剂盒、设备和仪器，尚未盈利，并产生亏损净额。2018财年至2019财年公司总营收分别为人民币3260.9万元及5568.5万元，同比增长70.77%；同期录得净亏损1.57亿元及5.34亿元。2020年前9个月，公司录得总营收5724.3万元，同比增长36.74%，录得净亏损8.52亿元。行业方面，中国生殖遗传学医疗器械市场相对而言属新兴市场且正在快速发展。受不孕率日益上升、对辅助生殖治疗（如试管婴儿）的需求不断增长、中国健康意识日益提升、基因检测的可购性和可用性不断增加以及技术进步所驱动，中国生殖遗传学医疗器械市场（按基于出厂价计算的销售收入计）已从2015年的人民币13亿元增长至2019年的人民币34亿元，复合年增长率为28.4%，并预期于2024年达到人民币112亿元，2019年至2024年的复合年增长率为26.5%。基石投资者方面，多名基石投资者同意按发售价认购可供认购的发售股份数目，总额约6.98亿港元，包括OrbiMed Funds、清池资本(Lake Bleu Prime )、CRF、AHAM、 WinTwin、Foresight Funds 及IvyRock Fund。筹资用途方面，公司拟将股份发售所得款项净额用于以下用途：约30%将分配予核心产品PGT-A试剂盒；约20%将用于PGT-M试剂盒的临床试验、注册申报及商业化；约30%将分配用于我们其他产品的开发、临床试验及注册申报；约10%将用于提高研发能力及提升技术；约10%将用作营运资本及一般企业用途。","news_type":1,"symbols_score_info":{"02170":0.9}},"isVote":1,"tweetType":1,"viewCount":2644,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3527667803686145","authorId":"3527667803686145","name":"社区成长助手","avatar":"https://static.tigerbbs.com/2b7c7106b5c0c8b0037faa67439d898f","crmLevel":1,"crmLevelSwitch":0,"idStr":"3527667803686145","authorIdStr":"3527667803686145"},"content":"Finally, when you first post [compare heart] [compare heart] post, you can get more exposure by related stocks or related topics. If you want to create high-quality articles, please checkGuidelines for Tiger Community Creation","text":"Finally, when you first post [compare heart] [compare heart] post, you can get more exposure by related stocks or related topics. If you want to create high-quality articles, please checkGuidelines for Tiger Community Creation","html":"Finally, when you first post [compare heart] [compare heart] post, you can get more exposure by related stocks or related topics. If you want to create high-quality articles, please checkGuidelines for Tiger Community Creation"}],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}